Sotorasib in Advanced KRAS p.G12C-Mutated NSCLC with Treated or Untreated Brain Metastases: Safety and Efficacy Data from the Global Expanded Access Program (EAP)

被引：0

作者：

Awad, M. M. ^{[1
]}

Pelizzari, G. ^{[2
]}

Stevenson, J. ^{[3
]}

Majem, M. ^{[4
]}

Ferreira, C. Gil ^{[5
]}

Petty, W. ^{[6
]}

Arriola, E. ^{[7
]}

De Castro, J. ^{[8
]}

Morbeck, I. ^{[9
]}

Bauman, J. ^{[10
]}

Toschi, L. ^{[11
]}

Zer, A. ^{[12
]}

Metro, G. ^{[13
]}

Kalmadi, S. ^{[14
]}

Azkarate, A. ^{[15
]}

Xia, C. ^{[16
]}

Meloni, A. ^{[16
]}

Obiozor, C. ^{[16
]}

Hsu, H. ^{[16
]}

Varrieur, T. ^{[16
]}

Ardito-Abraham, C. ^{[16
]}

Maimon, N. ^{[17
]}

Novello, S. ^{[18
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Azienda Sanitaria Univ Friuli Cent, Dipartimento Oncol Udine, Udine, Italy

[3] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH USA

[4] Hosp Santa Creu i Sant Pau, Dept Med Oncol, Barcelona, Spain

[5] Oncoclin Inst Res & Educ, Dept Educ & Res, Rio De Janeiro, Brazil

[6] Wake Forest Univ, Dept Hematol & Oncol, Sch Med, Winston Salem, NC USA

[7] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[8] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[9] Hosp Sirio Libanes, Ctr Oncol, Ctr Oncol Asa Sul, Brasilia, DF, Brazil

[10] Fox Chase Canc Ctr, Dept Hematol Oncol, Main Campus, Philadelphia, PA USA

[11] Ist Clin Humanitas, Dept Med Oncol, Rozzano, Italy

[12] Davidoff Canc Ctr, Rabin Med Ctr, Thorac Canc Serv, Petah Tiqwa, Israel

[13] Osped S Maria Misericordia, Dept Med Oncol, Perugia, Italy

[14] Ironwood Canc & Res Ctr, Dept Hematol & Med Oncol, Chandler, AZ USA

[15] Hosp Univ Son Espases, Dept Med Oncol, Palma de Mallorca, Spain

[16] Amgen Inc, Thousand Oaks, CA USA

[17] Sackler Sch Med, Div Oncol, Meir Med Ctr, Oncol Serv, Rishon Leziyyon, Israel

[18] Univ Torino Orbassano, Dept Oncol, Orbassano, Italy

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PP01.17

引用

页码：E17 / E17

页数：1

共 50 条

[41] Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing
Jiang, Yunlin
Zhao, Mingye
Liu, Ruolin
Zheng, Xueping
MEDICINE, 2023, 102 (50) : E36387
[42] First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety
Stridder, John H.
Satake, Hironaga
Hollebecque, Antoine
Sunakawa, Yu
Tomasini, Pascale
Bajor, David Lawrence
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
[43] Lorlatinib for advanced ROS1+non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Girard, N.
Girodet, S. Galland
Duruisseaux, M.
Avrillon, V.
Roch, B.
Otto, J.
Cadranel, J.
Coudurier, M.
Moro-Sibilot, D.
Egenod, T.
Lamy, R.
Bennouna, J.
Zalcman, G.
Ricordel, C.
Tillon, J.
Odier, L.
Besse, B.
Missy, P.
Westeel, V.
Baldacci, S.
ANNALS OF ONCOLOGY, 2020, 31 : S865 - S865
[44] Lorlatinib for advanced ALK plus non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Baldacci, S.
Besse, B.
Avrillon, V.
Mennecier, B.
Dubray-Longeras, P.
Mazieres, J.
Descourt, R.
Duruisseaux, M.
Quantin, X.
Doubre, H.
Monnet, I.
Moro-Sibilot, D.
Schneider, S.
Cousin, S.
Merle, P.
Otto, J.
Langlais, A.
Morin, F.
Westeel, V.
Girard, N.
ANNALS OF ONCOLOGY, 2020, 31 : S843 - S843
[45] Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)
Faehling, M.
Schumann, C.
Christopoulos, P.
Hoffknecht, P.
Alt, J.
Horn, M.
Eisenmann, S.
Schlenska-Lange, A.
Aries, S. P.
Sackmann, S.
Schuett, P.
Steger, F.
Christoph, D.
ANNALS OF ONCOLOGY, 2020, 31 : S806 - S807
[46] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
Reck, M.
Spira, A.
Besse, B.
Wolf, J.
Skoulidis, F.
Borghaei, H.
Goto, K.
Park, K.
Griesinger, F.
Font, E. F.
Boyer, M.
Barrios, C. H.
Goss, G.
Yang, H.
Obiozor, C.
Ramalingam, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
[47] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
Reck, M.
Spira, A.
Besse, B.
Wolf, J.
Skoulidis, F.
Borghaei, H.
Goto, K.
Park, K.
Griesinger, F.
Felip, E.
Boyer, M.
Barrios, C. H.
Goss, G.
Yang, H.
Obiozor, C.
Ramalingam, S. S.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
[48] Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
Hong, David S.
Kuboki, Yasutoshi
Strickler, John H.
Fakih, Marwan
Houssiau, Helene
Price, Timothy Jay
Elez, Elena
Siena, Salvatore
Chan, Emily
Nolte-Hippenmeyer, Jane
Cardona, Panli
Tran, Qui
Masuishi, Toshiki
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC
Cappuzzo, F.
Castro Junior, G.
Kang, J. H.
Wu, Y. L.
Brustugun, O. T.
Cheema, P. K.
Owonikoko, T. K.
Longin, A. S.
Duan, J.
Caparica, R.
Loong, H. H. F.
Chan, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E14 - E14
[50] KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
Cappuzzo, Federico
Castro, Gilberto
Kang, Jin-Hyoung
Wu, Yi-Long
Brustugun, Odd Terje
Cheema, Parneet Kaur
Owonikoko, Taofeek K.
Longin, Anne-Sophie
Boran, Aislyn
Duan, Jiawei
Caparica, Rafael
Loong, Herbert H. F.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →